Lynch Biologics, LLC is a medical technology company based in Franklin, Tennessee, USA, and like Geistlich, is committed to medical regeneration. With its advanced biotechnological solutions, the company has already been able to help numerous of patients restore lost bone or soft tissue. Particularly popular with clinicians is the proven product GEM 21S®. This product utilizes a growth factor, that is capable of accelerating the body's own regeneration. With this acquisition, Geistlich, as the world market leader in regenerative dentistry, strengthens its position in the USA and can serve customers even more comprehensively with its regenerative portfolio.
Dr. Ralf Halbach, CEO of Geistlich, comments: "The acquisition of Lynch Biologics demonstrates our commitment to the US and further enhances our portfolio of innovative products used worldwide. Our two companies complement each other perfectly in terms of scientific focus and expertise in regeneration. We have long admired the pioneering spirit of Dr. Sam Lynch and welcome him and his team to our company."
Geistlich and Lynch Biologics share a mission to advance new regenerative technologies in dentistry. The aim is to provide even better support for the healing of the body's own bones and tissues. To this end, the two companies have now joined forces to foster research, education, quality and safety. Dr. Sam Lynch, CEO of Lynch Biologics, described his enthusiasm: "I am so excited to combine Lynch Biologics together with Geistlich Pharma North America to bring new technologies to market for the benefit of patients."
Lynch Biologics operations will be added to Geistlich’s existing USA affiliate, Geistlich Pharma North America. Following the close of this acquisition, in conjunction with the Geistlich team, Dr. Lynch will continue to support existing and new customers through best-in-class clinical science and dental education, as well as assist in future growth of GEM 21S® and growth factor technology.